Amgen has pled guilty and agreed to pay $762 million in connection with its off-label marketing of Aranesp, an anemia drug. The company will pay $612 million to resolve civil False Claims Act allegations brought by ten separate whistleblowers. In addition to Amgen’s off-label marketing of Aranesp, the civil settlement resolves allegations that the company marketed Enbrel and Neulasta for off-label uses, paid kickbacks to encourage prescription of its drugs, and engaged in false price reporting for several of its drugs. Amgen will also pay $150 million in criminal fines and forfeiture.

Read the entire article, “Amgen Pleads Guilty, to Pay $762 Million to Settle False Claims Charge”